BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

BioLineRx Stock Performance

NASDAQ BLRX opened at $0.43 on Thursday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The stock’s fifty day moving average is $0.56 and its two-hundred day moving average is $0.64. The firm has a market capitalization of $34.29 million, a P/E ratio of -0.56 and a beta of 1.46. BioLineRx has a fifty-two week low of $0.39 and a fifty-two week high of $1.93.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. On average, research analysts anticipate that BioLineRx will post -0.25 earnings per share for the current year.

Institutional Trading of BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. CVI Holdings LLC acquired a new stake in BioLineRx Ltd. (NASDAQ:BLRX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 815,683 shares of the biotechnology company’s stock, valued at approximately $462,000. CVI Holdings LLC owned about 1.02% of BioLineRx as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.